Weight Loss Drug Linked to Higher Suicidal Thoughts

A recent study has raised concerns about the potential link between semaglutide, the active ingredient in popular weight-loss and diabetes medications like Wegovy and Ozempic, and suicidal ideation. Researchers conducted an analysis of the World Health Organization’s (WHO) database for adverse drug events, finding a slight increase in reports of suicidal thoughts and self-injurious behavior associated with semaglutide and liraglutide up until August 2023. However, lead author Chiara Gastaldon cautioned that these findings do not establish a causal relationship, as pharmacovigilance studies can only indicate associations. Novo Nordisk, the manufacturer of Ozempic and Wegovy, responded to the study, stating that both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) found no evidence linking the drug to suicidality. The study authors highlighted the need for further investigation into potential off-label use and the misuse of these medications, which may contribute to the observed adverse effects. Notably, combining semaglutide with antidepressants or benzodiazepines was associated with a significantly higher risk of suicidal thoughts. Despite the inconclusive nature of the investigations, experts noted that contradictory results in pharmacovigilance studies are common. Previous analyses from the EMA and FDA databases have suggested a potential signal for suicidal reactions related to GLP-1 receptor agonists. Additionally, research indicates that individuals with pre-existing mental health conditions, such as depression and anxiety, may be at a higher risk of suicide, particularly in the context of weight-loss surgeries and the expectations surrounding them.